TOP > 外国特許検索 > Inhibitor of hmgb protein-mediated immune response activation, and screening method

Inhibitor of hmgb protein-mediated immune response activation, and screening method

外国特許コード F130007602
整理番号 AF22-02WO
掲載日 2013年8月9日
出願国 カナダ
出願番号 2811501
公報番号 2811501
公報番号 2811501
出願日 平成23年9月14日(2011.9.14)
公報発行日 平成24年3月22日(2012.3.22)
公報発行日 平成29年1月10日(2017.1.10)
国際出願番号 JP2011071023
国際公開番号 WO2012036215
国際公開日 平成24年3月22日(2012.3.22)
優先権データ
  • 特願2010-209587 (2010.9.17) JP
  • 特願2011-138825 (2011.6.22) JP
  • 2011WO-JP71023 (2011.9.14) WO
発明の名称 (英語) Inhibitor of hmgb protein-mediated immune response activation, and screening method
発明の概要(英語) (CA2811501)
Provided is an inhibitor of HMGB protein-mediated immune response activation, comprising one or more compounds selected from the group consisting of phosphorothioate oligonucleotides and derivatives thereof.
Also provided is a method for screening an inhibitor or promoter of HMGB protein-mediated immune response activation, comprising: a mixing step of mixing an HMGB protein and a labeled nucleic acid in the presence and absence of a test substance; a assaying step of assaying the HMGB protein bound to the labeled nucleic acid; and a determination step of determining that the test substance is an inhibitor of HMGB protein-mediated immune response activation in the case that the quantity of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is less than the quantity of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance, and determining that the test substance is a promoter of HMGB protein-mediated immune response activation in the case that the quantity of the HMGB protein bound to the labeled nucleic acid in the presence of the test substance is greater than the quantity of the HMGB protein bound to the labeled nucleic acid in the absence of the test substance.
特許請求の範囲(英語) [claim1]
1. A phosphorothioate oligonucleotide for use in treating or preventing a disease selected from the group consisting of multiple sclerosis, excessive immune response to a dead cell, organ transplant rejection, autoimmune disease, inflammatory bowel disease, allergy, septicemia, tumor growth by inflammation and inflammatory disease caused by a nucleic acidcontaining pathogen, wherein the phosphorothioate oligonucleotide is characterized by absence of an unmethylated CG sequence and by a nucleotide sequence that consists of:
the nucleotide sequence as set forth in SEQ ID NO: 40;
or a nucleotide sequence having deletion, substitution, or addition of one to three nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to a high-mobility group box (HMGB) protein.
[claim2]
2. The phosphorothioate oligonucleotide for use according to claim 1
wherein the phosphorothioate oligonucleotide is characterized by a nucleotide sequence that consists of:
the nucleotide sequence as set forth in SEQ ID NO: 40;
or a nucleotide sequence having deletion, substitution, or addition of one nucleotide in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim3]
3. The phosphorothioate oligonucleotide for use according to claim 1
wherein the phosphorothioate oligonucleotide is characterized by a nucleotide sequence that consists of the nucleotide sequence as set forth in SEQ ID NO: 40.
[claim4]
4. The phosphorothioate oligonucleotide for use according to any one of claims 1
to 3, wherein the phosphorothioate oligonueleotide inhibits binding between a nucleic acid activating an immune response and an HMGB protein in a cell.
[claim5]
5. A composition for use in treating or preventing a disease selected from the group consisting of multiple sclerosis, excessive immune response to a dead cell, organ transplant rejection, autoimmune disease, inflammatory bowel disease, allergy, septicemia, tumor growth by inflammation and inflammatory disease caused by a nucleic acidcontaining pathogen, the composition comprising the phosphorothioate oligonucleotide as defined in any one of claims 1 to 4 and a pharmaceutically acceptable carrier.
[claim6]
6. Use of a phosphorothioate oligonucleotide for treating or preventing a disease selected from the group consisting of multiple sclerosis, excessive immune response to a dead cell, organ transplant rejection, autoimmune disease, inflammatory bowel disease, allergy, septicemia, tumor growth by inflammation and inflammatory disease caused by a nucleic acidcontaining pathogen, wherein the phosphorothioate oligonucleotide is characterized by absence of an unmethylated CG sequence and by a nucleotide sequence that consists of:
the nucleotide sequence as set forth in SEQ ID NO: 40;
or a nucleotide sequence having deletion, substitution, or addition of one to three nucleotides in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to a high-mobility group box (HMGB) protein.
[claim7]
7. The use according to claim 6 wherein the phosphorothioate oligonucleotide is characterized by a nucleotide sequence that consists of:
the nucleotide sequence as set forth in SEQ ID NO: 40;
or a nucleotide sequence having deletion, substitution, or addition of one nucleotide in the nucleotide sequence as set forth in SEQ ID NO: 40 and having a binding ability to an HMGB protein.
[claim8]
8. The use according to claim 6 wherein the phosphorothioate oligonucleotide is characterized by a nucleotide sequence that consists of the nucleotide sequence as set forth in
SEQ ID NO: 40.
[claim9]
9. The use according to any one of claims 6 to 8, wherein the phosphorothioate oligonucleotide inhibits binding between a nucleic acid activating an immune response and an
HMGB protein in a cell.
  • 出願人(英語)
  • JAPAN SCIENCE AND TECHNOLOGY AGENCY
  • 発明者(英語)
  • TANIGUCHI TADATSUGU
  • YANAI HIDEYUKI
国際特許分類(IPC)
参考情報 (研究プロジェクト等) CREST Etiological Basics of and Techniques for Treatment of Allergic and Autoimmune Diseases AREA
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close